Dianthus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-43.56	-28.48	-71.14	-74.94	-76.77	-57.6	-35.51	-9.74
Depreciation & Amortization	0.36	0.15	2.02	1.98	1.84	0.88	0.38	0.01
Share-Based Compensation	2.9	1.52	10.31	9.94	10	10.7	2.26	0.66
Other Operating Activities	3.44	-2.26	-0.72	-1.01	7.82	4.05	10.59	2.23
Operating Cash Flow	-36.86	-29.07	-59.53	-64.02	-57.1	-41.89	-22.26	-6.53
Capital Expenditures	-0.11	-0.14	-1.26	-0.4	-3.06	-7.66	-2.2	-0.14
Change in Investments	20.36	-59.68	44.69	-10.24	4.59	-84.04	0	0
Investing Cash Flow	20.25	-59.82	43.43	-10.64	1.53	-91.7	-2.2	-0.14
Share Issuance / Repurchase	0.01	0	89.9	68.04	62.3	89.94	0	0.01
Debt Issued / Paid	0	0	0	0	0	0	0	6.5
Other Financing Activities	133.57	96.68	-0.3	-0.3	-	52.21	71.48	4.2
Financing Cash Flow	133.57	96.68	89.6	67.74	62.3	142.15	71.49	10.71
Net Cash Flow	116.97	7.79	73.5	-6.92	6.73	8.56	47.02	4.04
Free Cash Flow	-36.97	-29.21	-60.8	-64.42	-60.16	-49.55	-24.46	-6.67
Free Cash Flow Margin	-1308.24%	-455.18%	-	-	-	-	-	-
Free Cash Flow Per Share	-7.17	-33.41	-17.70	-23.47	-26.01	-43.11	-210.78	-714.04

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).